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Background: A higher prevalence of coeliac disease has recently been reported among patients with HCV-related
chronic hepatitis. Moreover, development of clinically overt coeliac disease has been described in a number of
HCV-related chronic hepatitis patients during α-interferon therapy. This prospective study was designed to evaluate
1) the prevalence of coeliac disease in patients with HCV-related chronic hepatitis; 2) the prevalence of HCV
infection in patients with coeliac disease; 3) whether PEG interferon-α treatment might favour the development of
coeliac disease in patients with chronic hepatitis C.
Materials and methods: Two hundred-ten consecutive patients (M/F = 140/70, range of age 35–58 years, median
age 46.5 years) with biopsy proven chronic hepatitis C underwent serological screening for antiendomysial and
tissue transglutaminase IgA antibodies. One hundred ninety-four coeliac patients (M/F = 52/142, range of age
18–74 years, median age 34 years) were screened for HCV antibodies. Positivity for HCV antibodies in coeliac
disease patients was confirmed by detection of serum HCV-RNA by RT-PCR. This work was carried out in
accordance to ethical guidelines of Declaration of Helsinki and was approved by Institutional Ethics Committee of
the Second University of Naples. All patients gave informed written consent.
Results: 1) none of the 210 HCV-related chronic hepatitis patients were positive for coeliac disease serologic
screening; 2) prevalence of HCV infection among coeliac patients was 1.54% (3/194) which is comparable to that
reported in the Southern Italy population; 3) PEG interferon-α treatment was not associated with development of
coeliac disease either clinical or serological.
Conclusions: 1) coeliac disease is not associated with HCV infection; 2) PEG interferon-α does not trigger celiac
disease.
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Coeliac disease (CD) is a condition characterized by
damage to the mucosa of the small bowel in sensitive
individuals and subsequent malabsorption, with a preva-
lence in the Western Countries of about 1/100 [1-3].
The clinical spectrum ranges from overt malabsorption
to no clinical signs when the damage of the small intes-
tine mucosa is mild (i.e. latent CD) [1]. CD is the only
human autoimmune disease in which an environmental* Correspondence: antonietta.gravina@yahoo.it
†Equal contributors
1Department of Clinical and Experimental Medicine and Surgery “F Magrassi
e A Lanzara” – Hepato-Gastroenterology Division and C.I.R.A.N.A.D., Second
University of Naples, via Pansini 5, Naples 80131, Italy
Full list of author information is available at the end of the article
© 2012 Gravina et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfactor (i.e., gluten) has been identified that triggers an
immune-mediated injury to the intestine in genetically
predisposed individuals [4,5].
Hepatitis C virus (HCV) infection is the major cause
of chronic liver disease worldwide [6]. Moreover, HCV
infection is associated with a number of autoimmune
disorders such as cryoglobulinemia, Sjogren syndrome,
and lichen planus [7,8].
Even though the association between CD and liver dis-
eases has been extensively investigated, a definite correl-
ation between these pathological conditions has not
been unequivocally established. An increased prevalence
of CD has been described by Fine et al. in patients with
HCV-related chronic hepatitis, thus leading to speculatel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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related chronic hepatitis [9]. In this study, four patients
tested positive for specific markers of CD among 259
patients infected with HCV [9]. In another study, one
patient with CD was found to have HCV infection when
investigators looked for causes of increased alanine ami-
notransferases (ALT) levels in this setting [10]. Also,
liver involvement is a frequent finding in CD patients
[11]. On the other hand, Germenis et al. found a 0.54%
prevalence of positive CD serology among 738 patients
with liver disease, which was not different than what
found in the general population [12]. Therefore, whether
CD is part of the spectrum of HCV infection-related
autoimmune disorders is still controversial [13].
A number of cases of clinically overt CD have been
described in patients with HCV-related chronic hepatitis
during treatment with interferon alpha (IFN-α) [14-17].
Also, Hernandez et al. [18] suggested that IFN-α may pre-
cipitate the development of CD in susceptible individuals.
On the other hand Ruggeri et al. failed to demonstrate
development of positive CD serology in 42 HCV-infected
patients treated with IFN-α. Therefore, whether IFN-α is
able to trigger CD is still unclear.
In order to specifically address these issues we
designed a prospective study aimed at evaluating the
prevalence of CD in patients with HCV-related chronic
hepatitis and the prevalence of HCV infection in a popu-
lation of patients with CD. Moreover, we studied
whether pegylated (PEG) IFN-α treatment might be
associated with the development of CD.
Methods
HCV-related chronic hepatitis patients
The study population consisted of 210 consecutive
patients (M/F = 140/70, range of age 35–58 years, me-
dian age 46.5) with a biopsy proven HCV-related chronic
hepatitis enrolled from September 2008 to July 2010.
All these patients were tested for routine liver function
tests (i.e., aminotranferases, γ-glutamyltranspeptidase,
alkaline phosphatase, bilirubin, prothrombin activity, cho-
linesterase), immunoglobulins (Ig)A, IgG, and IgM, plate-
let count, blood cell count, haemoglobin, albumin,
HBsAg, HBsAb, HBcAb (IgM-IgG), HBeAg, HBeAb,
HCVAb, ANA, AMA, SMA, anti-LKM, plasma iron and
copper levels, ceruloplasmin and ferritin and for anti-
bodies against endomysium (EMA) tested on thin sections
of human cord using an indirect immunofluorescent
method and for tissue transglutaminase (tTG) by using
ELISA assays. All underwent ultrasonography.
One hundred and sixty eight patients with HCV-
related chronic hepatitis naïve to treatment (M/F = 125/
43, range of age 35–52 years, median age 44) were eli-
gible for interferon therapy and were treated with stand-
ard of care (PEG interferon-α plus ribavirin). Thesepatients underwent screening for coeliac disease before
the treatment and at 24 and 48 week of treatment.
This work was carried out in accordance to ethical
guidelines of Declaration of Helsinki and was approved
by Institutional Ethics Committee of the Second Univer-
sity of Naples. All patients gave informed written
consent.
RNA preparation and HCV-RNA determination
All steps were carried out under RNase-free conditions.
The polymerase chain reaction (PCR) procedure was
used to determine HCV RNA. Sera were rapidly (within
30 min of blood drawing) frozen at −20°C. RNA was
extracted according to Chomczynsky and Sacchi [19],
and c-DNA was derived. To identify HCV-RNA, a
nested PCR was performed using primers that expanded
the highly conserved 5’ non-coding genomic region. Car-
ryover PCR contamination was avoided by applying the
measures suggested by Kwok and Higuchi [20]. Limit of
the house virus detection test applied was of 10 copies/ml.
HCV genotyping
The genotype analysis of HCV was performed using a
commercial hybridization assay (Inno Lipa HCV II;
Innogenetics, Gent, Belgium); utilizing HCV-positive
amplification products from the PCR assay (Amplicor
HCV Amplification 2.0; Roche Diagnostics, Indianapolis,
IN, USA). Serum PCR products were hybridized to type-
and subtype-specific probes 1a, 1b, 2a, 2b and 3a, in
order to classify the HCV genotypes. The probes used
were to fulfill two main criteria: no more than two mis-
matches to three corresponding published sequences of
the same subtype and they were to differ by three or
more mismatches compared to published sequences of
other types and subtypes. The only exception is probe
2b showing only two mismatches to the corresponding
sequence of type 3a [21].
Liver biopsy and histology
Hepatic percutaneous biopsy was performed with a
Surecut 17G needle via the intercostal route and an
echo-assisted method. Liver specimens were used for
histological examination if they were at least 1.5-cm long
and contained ≥ 5 portal spaces. Specimens were fixed in
formalin, embedded in paraffin, and stained with
hematoxylin-eosin, Red Sirius, Ubiquitin, trichrome, and
Prussian blue. Steatosis was graded 1 (<33% of hepato-
cytes), 2 (33-66% of hepatocytes), 3 (>66% of hepato-
cytes). Biopsies were evaluated with the Ishak score [22],
and biopsies with steatosis were also scored according to
Brunt’s criteria [23]. Table 1 includes the main clinical
and laboratory characteristics of patients with HCV-
related chronic hepatitis.
Table 1 Main clinical, biochemical and histological




Age (years; mean ± SD) 46.5 ± 11.56
Body Mass Index (mean ± SD) 26.7 ± 4.01
HCV-RNA levels (I.U./mL; mean ± SD) 4.318.618 ± 28.174
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We also studied 194 coeliac patients (M/F = 52/142,
range of age 18–74 years, median age 34 years). The
diagnostic workup included a thorough medical history,
routine biochemistry, determination of serological mar-
kers of HBV and HCV infection. CD diagnosis was made
on the basis of positivity to EMA and tTG of histological
evaluation of duodenal biopsy samples showing subtotal/
total villous atrophy, crypt hyperplasia and lympho-
plasmacellular infiltration in the lamina propria [24].
Table 2 indicates the prevalence of associated auto-
immune disorders in our coeliac patients. Coeliac
patients who were positive for HCV antibodies were also
tested for serum qualitative and quantitative HCV-RNA
and HCV genotyping.Statistical analysis
Difference between groups was assessed by Fisher’s exact
test. A value of p < 0.05 was considered statistically
significant.Table 2 Prevalence of autoimmune disorders in our series
of 194 coeliac subjects
N (%)
Hashimoto thyroiditis 32 16.5
Dermatitis herpetiformis 2 1.0
Alopecia 1 0.5
Vitiligo 1 0.5
Primary biliary cirrhosis 1 0.5
Recurrent oral aphtosys 1 0.5
IgA mesangial nephropathy 1 0.5Results
None of the 210 patients with HCV-related chronic liver
disease resulted positive to serological screening for CD,
nor did any of them show deficiency for IgA (Table 3).
Furthermore, 3/194 (1.54%) CD patients were positive
for both HCV antibodies and qualitative HCV-RNA in
the serum (Table 3). This is comparable to the preva-
lence of HCV infection in Southern Italy [25]. One of
the HCV positive CD patients had a history of intraven-
ous heroine use, one had received blood transfusions for
anemia before the diagnosis of CD was made and one
was married to an HCV positive subject. Table 4 shows
the main features and the degree of duodenal damage at
histology of the HCV positive CD subjects.
In order to assess whether IFN-α treatment might trig-
ger CD we determined serum EMA and tTG in HCV-
related chronic hepatitis patients before the treatment
and at 24 and 48 week of treatment. One hundred and
thirty patients completed the therapy, while thirty-eight
discontinued for serious adverse events (54% anemia,
34% leukopenia, 12% thrombocytopenia). A virological
(i.e. disappearance of serum HVCV-RNA) and biochem-
ical (normal AST and ALT serum levels) was observed at
the end of treatment in 91/130 (70%) of patients. None
of the 130 patients who completed therapy turned posi-
tive for EMA or tTG nor did any of them develop clin-
ical signs or symptoms suggestive for CD at any time
point during the follow-up period.
Discussion
Viral infections have been thought to act as a potential
trigger for the development of CD in genetically suscep-
tible individuals [26,27]. In particular, because of its as-
sociation with a number of autoimmune disorders, the
role of HCV infection in the pathogenesis of CD has
been the object of several investigations, but the results
are controversial [9-13].
In order to specifically address this issue we prospect-
ively evaluated the prevalence of CD in 210 HCV-related
chronic hepatitis patients. None of these patients had clin-
ical signs or symptoms suggestive for CD nor did any of
them show positivity for serological markers of CD (EMA
and/or tTG). Moreover, in a population of 194 CD
patients, we found a prevalence of HCV infection as low
as 1.54%, which is not higher than the prevalence of HCV
infection in Southern Italy [25]. Also, all of the CD
patients who resulted HCV positive were at risk for HCV
infection. This suggests that HCV-related chronic hepa-
titis and CD are not associated disorders. In partial sup-
port of our finding, Teml and Vogelsang in a retrospective
study found that 3/488 (0.6%) CD patients were positive
for HCV infection [13]. However, all of them were at risk
for HCV infection, one patient having a history of i.v. drug
abuse and two having received blood transfusion because
Table 3 Prevalence of coeliac disease in HCV-related
chronic hepatitis patients and prevalence of HCV-related
chronic hepatitis in coeliac disease patients
HCV-related chronic hepatitis Coeliac disease
(n = 210) (n = 194)
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found 0% prevalence of CD in 624 consecutive patients
with HCV infection [28]. Finally, our results are in agree-
ment with the findings of Hernandez et al. who found no
association between CD and HCV both in a retrospective
and prospective analysis [18]. However, a report by
Ruggeri et al. investigated CD-related antibodies in a
large series of HCV-infected subjects that were also tested
for non-organ-specific autoantibodies as surrogate marker
of autoimmune disorders. The authors found that EMA
occurred in 5/244 (2%) of HCV patients, which was sig-
nificantly higher than the prevalence of EMA positivity
found in healthy controls [29]. However, only in three of
these patients CD was confirmed histologically and, in
one of them, non-organ-specific autoantibodies were
positive [29].
IFN-α treatment has been shown to potentially trigger
autoimmune disorders [22]. Also, development of clinic-
ally overt CD has been described in patients with
HCV-related chronic hepatitis during IFN-α treatment
[14-17]. However, in these reports, half of the patients
were EMA and tTG positive with no clinical or bio-
chemical signs of malabsorption before starting IFN-α
therapy whereas the EMA and tTG status was not avail-
able in the remaining patients. This suggests that IFN-α
may trigger overt CD in asymptomatic EMA and tTG
positive subjects (i.e. latent CD patients). However, the
question as to whether IFN treatment may induce EMA
and tTG positivity with/without malabsorption remains





Liver fibrosis score 2
Risk factors for HCV infection History of i.v.
heroin use




weakness, bloatingEMA and tTG negative, chronic hepatitis C patients
might develop clinically overt or latent CD during IFN-α
plus ribavirin combined therapy. None of these patients
showed clinical signs or symptoms suggestive for CD or
positivity for EMA and tTG before or after treatment,
thus making it unlikely that IFN-α may serve as a trigger
for CD. This is also in agreement with Ruggeri et al.
who found no CD-related antibody in 42 HCV-infected
patients treated with IFN-α [29]. More recently, Hernandez
et al. found that 6/878 CD patients had concomitant HCV
infection and that in four of these 6 patients, symptoms
that prompted CD diagnosis occurred during or after IFN-
α therapy. This may suggest that IFN-α therapy may pre-
cipitate the development of CD in susceptible individuals.
However, none of these subjects had been screened for CD
prior to start IFN-α therapy [18].
A limit of this study is represented by the small num-
ber of patients studied. Also, this study lacked a control
group of patients with chronic hepatitis other than HCV-
related. However, we evaluated the prevalence of coeliac
disease in a group of 131 patients with non alcoholic fatty
liver disease (NAFLD) who were admitted to our GI Unit
over the same period of time and found that none of
these patients had a serology positive for coeliac disease
(Romano M and Persico M unpublished observation).
Similarly, the prevalence of HCV infection found in our
coeliac patients (i.e. 1.5%) is comparable to that found in
315 non coeliac patients who underwent screening for
HCV prior to esophagogastroduodenoscopy (i.e. 1.7%, p,
ns) (Romano M unpublished observation).
Conclusions
In summary, 1) none of HCV infected patients showed
positivity for CD serology; 2) prevalence of HCV infec-
tion among CD patients was comparable to that of gen-
eral population; 3) none of IFN-α-treated HCV patients
developed CD. Based on this study, we conclude that
HCV infection and CD do not seem to be epidemiologi-
cally associated. Moreover, IFN-α treatment seems un-
likely to cause CD.patients








Marsh III a Marsh III b
Syderopenic anaemia Chronic diarrhoea, weight
loss, syderopenic anaemia
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